Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Celyad Oncology stock

Learn how to easily invest in Celyad Oncology stock.

Celyad Oncology SA is a biotechnology business based in the US. Celyad Oncology shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad Oncology employs 87 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Celyad Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYAD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Celyad Oncology stock price (NASDAQ: CYAD)

Use our graph to track the performance of CYAD stocks over time.

Celyad Oncology shares at a glance

Information last updated 2022-01-23.
Latest market close$3.71
52-week range$3.50 - $8.57
50-day moving average $4.01
200-day moving average $4.72
Wall St. target price$11.90
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.35

Buy Celyad Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Celyad Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celyad Oncology price performance over time

Historical closes compared with the close of $3.71 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-22) N/A
3 months (2021-10-22) -25.50%
6 months (2021-07-26) -19.00%
1 year (2021-01-26) -55.14%
2 years (2020-01-24) -66.58%
3 years (2019-01-25) 22.4
5 years (2017-01-26) 21.71

Celyad Oncology financials

Gross profit TTM $5,000
Return on assets TTM -22.61%
Return on equity TTM -56.04%
Profit margin 0%
Book value $1.22
Market capitalisation $89 million

TTM: trailing 12 months

Celyad Oncology share dividends

We're not expecting Celyad Oncology to pay a dividend over the next 12 months.

Celyad Oncology share price volatility

Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $3.5 up to $8.57. A popular way to gauge a stock's volatility is its "beta".

CYAD.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.318. This would suggest that Celyad Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celyad Oncology overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .

Frequently asked questions

What percentage of Celyad Oncology is owned by insiders or institutions?
Currently 0.074% of Celyad Oncology shares are held by insiders and 1.246% by institutions.
How many people work for Celyad Oncology?
Latest data suggests 87 work at Celyad Oncology.
When does the fiscal year end for Celyad Oncology?
Celyad Oncology's fiscal year ends in December.
Where is Celyad Oncology based?
Celyad Oncology's address is: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
What is Celyad Oncology's ISIN number?
Celyad Oncology's international securities identification number is: US1512052002
What is Celyad Oncology's CUSIP number?
Celyad Oncology's Committee on Uniform Securities Identification Procedures number is: 151205200

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site